Mr. DU Bo, our founder and Chief Executive Officer (CEO), is a pioneer in the NGS precision medicine industry in China. He founded China’s first NGS reagent company, Nanjing Questgenomics Biotechnology Co., Ltd. Mr. DU is currently a member of the CSCO and a member of the Clinical Research Professional Committee of Beijing Cancer Society. He has well-rounded and extensive experience in pharmaceuticals and NGS, and has a distinguished strategic vision in our business.

Mr. MA Guosheng, our executive vice president, previously worked in senior sales leadership positions for Bristol-Myers Squibb, Sanofi Aventis, Merck Serono and other well-known multinational pharmaceutical companies, and has more than 20 years of sales and marketing management experience in the field of oncology drugs.

Dr. CHEN Weizhi, our Chief Science Officer (CSO), has a combined background in medicine and molecular biology and more than 20 years of experience in biotechnology research in both China and the United States. Dr. CHEN has gained extensive knowledge in all aspects of high-throughput genomics research with a specialty in NGS applications in clinical space. She is the inventor of 38 patents globally, many of which are related to our key products and technologies. Previously, she served as the head of R&D in GENEWIZ China and Simcere Diagnostics.